| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM196409242711302 |
| P698 | PubMed publication ID | 14170843 |
| P2093 | author name string | WHEELOCK EF | |
| DINGLE JH | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| leukemia | Q29496 | ||
| P304 | page(s) | 645-651 | |
| P577 | publication date | 1964-09-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | OBSERVATIONS ON THE REPEATED ADMINISTRATION OF VIRUSES TO A PATIENT WITH ACUTE LEUKEMIA. A PRELIMINARY REPORT. | |
| P478 | volume | 271 |
| Q78559082 | ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN |
| Q40049579 | Anemias of Infection |
| Q39484906 | Apoptin enhances the oncolytic properties of Newcastle disease virus |
| Q39533450 | Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus |
| Q36720873 | Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress |
| Q90134243 | Development of oncolytic virotherapy: from genetic modification to combination therapy |
| Q34427532 | Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo |
| Q34113068 | Enhanced interferon response to murine leukemia virus by ascorbic acid |
| Q53739132 | Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! |
| Q42230898 | Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain |
| Q44319257 | Genetically engineered Newcastle disease virus for prostate cancer: a magic bullet or a misfit |
| Q71157837 | Infectious diseases. Annual review of significant publications |
| Q40561329 | Interferon Production in Leukaemia |
| Q27480942 | Interferon: a changing picture |
| Q40102336 | Interferons and interferon inducers: development of clinical usefulness and therapeutic promise |
| Q90257528 | Intratumoral Immunotherapy-Update 2019 |
| Q35721486 | Mechanisms of Oncolysis by Paramyxovirus Sendai |
| Q70978946 | Mixed viral infection: rubella and varicella in a patient with acute leukemia |
| Q54734491 | Morbilliform exanthema in leukoses under chemotherapy |
| Q35898239 | Mumps and enteroviral meningitis in Toronto, 1966 |
| Q37972664 | Newcastle disease virus: a promising agent for tumour immunotherapy |
| Q37535829 | Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer |
| Q34057238 | Nonspecific enhancers of resistance in man |
| Q35861933 | Oncolysis by paramyxoviruses: preclinical and clinical studies. |
| Q38369289 | Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host |
| Q37990940 | Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions |
| Q42834375 | Oncolytic effect of bovine enterovirus on mouse and human tumours. |
| Q39437344 | Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer |
| Q37533665 | Oncolytic viral therapy of malignant glioma |
| Q37615535 | Oncolytic virus therapy for prostate cancer |
| Q78595329 | Oncolytic viruses |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q38264443 | Oncolytic viruses in head and neck cancer: a new ray of hope in the management protocol |
| Q35610296 | Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas |
| Q39747959 | Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus |
| Q27480945 | The effects of therapeutic measures in diseases caused by viruses |
| Q68632224 | The relationship between serum interferon and an inhibitor of mouse haemopoietic colonies in vitro |
| Q35050645 | Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer |
| Q38924554 | Therapeutic potential of oncolytic Newcastle disease virus: a critical review |
| Q40108900 | Treatment of Acute Leukemia–Advances in Chemotherapy, Immunotherapy, and Bone Marrow Transplantation |
| Q37642230 | Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy |
| Q37028023 | Trial watch: Oncolytic viruses for cancer therapy |
| Q61819636 | VIRUSES IN THE TREATMENT OF CANCER |
| Q50244673 | Virus Treatment of Leukoses |
| Q37473930 | Viruses as an aid to cancer therapy: regression of solid and ascites tumors in rodents after treatment with bovine enterovirus |
Search more.